Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Clin Cancer Res. 2018 Apr 4;24(14):3299–3308. doi: 10.1158/1078-0432.CCR-17-3008

Table 1.

Contingency table evaluating the association between HDI and non-responsiveness to ipilimumab treatment. Two-tailed Fisher Exact test, P = 0.0029, odds ratio (OR) = 11.8. HDI, homozygous deletion of type-I interferons.

Type-I IFNs
(Homozygous deletion)
Type-I IFNs
(1 or more copies)
Total
Non-responder 18 54 72
Responder + Long-term survivor 1 36 37
Total 19 90 109